Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent Troll Bill Clears House; Provisions Problematic For PhRMA Remain

This article was originally published in The Pink Sheet Daily

Executive Summary

Amendments make things a little better for drug firms as attention now shifts to the Senate version.

You may also be interested in...

Government Briefs: White House Moves On Patent Reform, DOJ Settles Endo Off-Label Complaints

Endo admits to marketing its post-herpetic neuralgia pain drug Lidoderm for unapproved uses in a $192.7 million settlement; National Economic Council Director says there is “a sweet spot for bipartisan compromise” on patent troll bills introduced in the House and Senate.

Drug Firms Ask Senate For Narrow Patent Troll Bill

“One-size-fits-all” patent troll bill will harm innovators, Johnson & Johnson’s chief IP counsel tells Senate hearing.

PTO’s New Deputy Director To Push For “Good IP Policy” Across Industries

Michelle Lee, former deputy general counsel of Google, is to lead Patent and Trademark Office until a permanent director is named; new patent reform legislation will be among her areas of focus.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts